Navigation Links
Mylan Launches Generic Version of Toprol-XL® Tablets
Date:12/16/2011

PITTSBURGH, Dec. 16, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Metoprolol Succinate Extended-release (ER) Tablets USP, 25 mg, 50 mg, 100 mg, and 200 mg. This product is the generic version of AstraZeneca's Toprol-XL® Tablets, which are indicated for the treatment of hypertension.

Metoprolol Succinate ER Tablets had U.S. sales of approximately $1.78 billion for the 12 months ending Sept. 30, 2011, according to IMS Health. Mylan's launch of this product is representative of the company's strength in continuing to bring difficult-to-formulate medicines to market.

Currently, Mylan has 166 ANDAs pending FDA approval representing $98.3 billion in annual sales, according to IMS Health. Forty-three of these pending ANDAs are potential first-to-file opportunities, representing $26.9 billion in annual brand sales, for the 12 months ending June 30, 2011, according to IMS Health.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit www.mylan.com. For more information about generic drugs, please visit www.ChoosingGenerics.com.

 


'/>"/>
SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Mylan Announces Settlement Agreement Related to Antidepressant Effexor XR(R)
2. Mylan Receives FDA Approval for Generic Version of Parkinsons Treatment Sinemet(R)
3. Mylan Schedules Third Quarter 2009 Financial Results Conference Call and Live Webcast
4. Mylan Receives FDA Approval for Generic Version of Anticonvulsant Topamax(R) Sprinkle Capsules
5. Mylan Confirms First-to-File Patent Challenge Relating to Caduet(R)
6. Mylan Receives Approval for Generic Version of GoLytely(R)
7. Mylan Declares Quarterly Preferred Stock Dividend
8. Mylan Pre-Pays All Scheduled 2011 Term-Loan Borrowings
9. Mylan Confirms First-to-File Patent Challenge Relating to Vytorin(R) Cholesterol Medication
10. Mylans President of Europe, Middle East and Africa Elected President of European Generic Medicines Association
11. Mylan Receives Tentative FDA Approval Under PEPFAR for Matrix Laboratories New Drug Application (NDA) for Efavirenz Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... Dec. 9, 2016  Axovant Sciences Ltd. (NYSE: ... company focused on the treatment of dementia, today ... a Phase 2b trial evaluating treatment with intepirdine ... with donepezil plus placebo in people with mild-to-moderate ... of intepirdine to treatment was associated with reduced ...
(Date:12/8/2016)... -- KEY FINDINGS ... Patient warming and cooling devices offer ... lowering the risks of neurological disorders post cardiac arrests, rapid ... warming systems can be segmented into convective warming system, surface ... the stay at hospitals thus, lowering the healthcare costs by ...
(Date:12/8/2016)... Inc. (NYSE: DPLO) has been recognized by the Detroit Free ... To learn more about Diplomat,s career opportunities, visit ... ... ... a research firm specializing in organizational health and workplace improvement. The ...
Breaking Medicine Technology:
(Date:12/10/2016)... ... December 09, 2016 , ... Even with breast cancer ... greatly in recent years. This can be attributed to the improvement in breast ... equally distributed. In response, Mediaplanet’s latest, cross-platform edition of “Breast Cancer Care” spotlights ...
(Date:12/10/2016)... ... December 10, 2016 , ... Denver-based humanitarian aid organization, ... war—babies and toddlers. , The situation in Syria continues to worsen—deadly weapon explosions ... and dying from disease. The situation is intensifying with winter coming and airstrikes ...
(Date:12/9/2016)... ... , ... Cellairis is a worldwide mobile device and computer repair franchise that ... and Samsung Galaxy devices with premium parts and accessories. Cellairis has recently set-up ... accessibility for customers. While customers do their shopping, Cellairis can accomplish a number of ...
(Date:12/9/2016)... ... 09, 2016 , ... Sober College, the game-changing dual diagnosis ... of the Sober College Robert Pfeifer Memorial Learning Center at its location in ... attended by an overwhelming amount of alumni, family, colleagues and friends of Sober ...
(Date:12/9/2016)... ... 09, 2016 , ... MEDI+SIGN®, a provider of fully-automated patient ... solution for Emergency Departments (ED) has been added to their portfolio. Housed in ... rooms, and with a simplified pallet of information available to the patient, the ...
Breaking Medicine News(10 mins):